{
  "@context": "aku-v2",
  "@type": "pharmacology",
  "@id": "vasc:pharm:bridge-anticoagulation",
  "metadata": {
    "version": "2.0.0",
    "created": "2026-01-07T03:26:00.000Z",
    "updated": "2026-01-07T03:26:00.000Z",
    "contributors": ["knowledge-graph-agent"],
    "confidence": 0.92,
    "status": "pending-quality-check"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pharmacology",
    "type": "perioperative-management",
    "difficulty": "intermediate",
    "importance": "high"
  },
  "content": {
    "title": "Bridge Anticoagulation",
    "description": "Perioperative anticoagulation management for patients on warfarin",
    "key_concepts": [
      {
        "concept": "Indications",
        "details": "Consider for high-risk patients: mechanical valve, recent VTE, high CHADS2-VASc"
      },
      {
        "concept": "BRIDGE Trial",
        "details": "No bridging non-inferior to bridging for AF; increased bleeding with bridging"
      },
      {
        "concept": "Current Practice",
        "details": "Most AF patients do NOT need bridging; individualize based on thromboembolic risk"
      },
      {
        "concept": "Timing",
        "details": "Stop warfarin 5 days pre-op; start LMWH when INR subtherapeutic; stop LMWH 24h pre-op"
      }
    ],
    "clinical_significance": "Trend toward less bridging due to bleeding risk"
  },
  "provenance": {
    "primary_sources": ["Douketis JD et al. N Engl J Med 2015"]
  }
}
